The PReSUTINeB trial will investigate if Uro Vaxom can reduce the incidence of symptomatic UTIs in 48 participants in two centres in the UK (Stoke Mandeville Hospital, Buckinghamshire and Oxford Centre for Enablement). The trial has now recruited its first patient at the Oxford Centre for Enablement. The investigators will also look at the signs and symptoms a participant experiences during a symptomatic UTI.
First patient recruited to PReSUTINeB Trial
- 16 April 2018